Rua Bioscience, an export-led company, has announced that it will cease local GMP manufacturing and accelerate its global brand strategy.
Working with manufacturing partners, the company hopes to provide New Zealand patients with a wider range of affordable medicines.
The company is focusing on the high-growth European medicinal cannabis market and is also assessing commercial opportunities in Australia.
This change results in the loss of two employees.
See more
